NBE Therapeutics
Updated: November 22, 2025
Ulf Grawunder - founder and CEO
Country: Switzerland | Funding: $65.7M (+)
Website: http://www.nbe-therapeutics.com
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
Website: http://www.nbe-therapeutics.com
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
